Sponsor: Janux Therapeutics
Sponsor Study ID: Janux PSMA-007-001
Study Title: A Phase 1, Open-Label, Multicenter Study of Janx007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
CTO #: 104144
NCT Number: NCT05519449
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Prostate
Study Objectives: To assess safety and tolerability in subjects with mCRPC to determine the MTD-R or MAD and to assess potential Phase 2 dose regimens and determine a RP2D-R. To assess the safety and tolerability of JANX007 when administered with recombinant human albumin (rHA). To compare the safety and tolerability of 2 potential RP2D-Rs identified from Part 1 and Part 2. To assess the safety and tolerability in taxane naïve subjects with mCRPC.